HALO
Halozyme Therapeutics, Inc.
$38.19
Earnings Summary
Revenue | $39Mn |
Net Profits | $-27.39Mn |
Net Profit Margins | -70.22% |
Highlights
Halozyme Therapeutics, Inc.’s revenue fell -25.32% since last year same period to $39Mn in the Q4 2016. On a quarterly growth basis, Halozyme Therapeutics, Inc. has generated 22.45% jump in its revenue since last 3-months.
Halozyme Therapeutics, Inc.’s net profit fell -734.23% since last year same period to $-27.39Mn in the Q4 2016. On a quarterly growth basis, Halozyme Therapeutics, Inc. has generated 5.39% jump in its net profits since last 3-months.
Halozyme Therapeutics, Inc.’s net profit margin fell -949.26% since last year same period to -70.22% in the Q4 2016. On a quarterly growth basis, Halozyme Therapeutics, Inc. has generated 22.73% jump in its net profit margins since last 3-months.
Earnings per share (EPS) Estimates
Earnings per share (EPS) estimates of the Halozyme Therapeutics, Inc. post its latest quarter earnings
EPS Estimate Current Quarter | 0.47 |
EPS Estimate Current Year | 0.47 |
Highlights
Halozyme Therapeutics, Inc.’s earning per share (EPS) estimates for the current quarter stand at 0.47 - a -7.84% fall from last quarter’s estimates.
Halozyme Therapeutics, Inc.’s earning per share (EPS) estimates for the current year stand at 0.47.
Key Ratios
Key ratios of the Halozyme Therapeutics, Inc. post its Q4 2022 earnings
Return on Assets (ROA) | 0.12 |
Return on Equity (ROE) | 1.1 |
Highlights
Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Halozyme Therapeutics, Inc.’s return on assets (ROA) stands at 0.12.
The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Halozyme Therapeutics, Inc.’s return on equity (ROE) stands at 1.1.
Earnings Calendar
| Earnings Date | Estimated EPS | Reported EPS | Surprise % |
|---|---|---|---|
2020-11-02 | 0.2 | 0.25 | 25% |
2020-08-10 | 0.25 | 0.19 | -24% |
2020-05-11 | -0.02 | -0.04 | -100% |
2021-02-23 | 0.53 | 0.5 | -5.66% |
Company Information
Halozyme is a biopharmaceutical company focused on bringing disruptive solutions to significantly improve patient experiences and outcomes for emerging and established therapies. Halozyme advises and supports its biopharmaceutical partners in key aspects of new drug development with the goal of improving patients' lives while helping its partners achieve global commercial success. Halozyme's proprietary enzyme rHuPH20 forms the basis of the ENHANZE® technology and is used to facilitate the delivery of injected drugs and fluids, potentially reducing the treatment burden of other drugs to patients. Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Baxalta, Pfizer, Janssen, AbbVie, Lilly, Bristol-Myers Squibb, Alexion, argenx and Horizon Therapeutics. Halozyme derives revenues from these collaborations in the form of milestones and royalties as the Company's partners make progress developing and commercializing their products being developed with ENHANZE®. Halozyme is headquartered in San Diego.
Organisation | Halozyme Therapeutics, Inc. |
Headquarters | 11388 Sorrento Valley Road, San Diego, CA, United States, 92121 |
Employees | 393 |
Industry | Health Technology |
CEO | Helen Torley |
